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in Clinical Trials Using Mixed ModesCongratulations to the ISPOR PRO Mixed Modes Good Research
Practices Task Force [1] for tackling a challenging question that
many patient-reported outcome (PRO) researchers have pondered
either publicly or privately as they review PRO results tables
based on data collected through a combination of data collection
methods: “Would these results and the study conclusions be
different if the same mode had been employed?” The report’s
general recommendation to “Just say no!” to mixing modes
within a single study (or set of studies that may be pooled) is
good advice and, if followed, will save many headaches and
resources. If ignored and data are combined without considera-
tion of the guidance offered in this report, post hoc evaluations
may be necessary to backﬁll evidence to support the fact that the
PRO data and conclusions are not compromised, especially to
support medical product labeling.
The task force report is well written and provides an enor-
mous amount of information about the current technologies
available for PRO data collection. There is a deep dive into the
issues of mixed modes from a technology, formatting, and
qualitative perspective. The recommendations for a “faithful
migration” are detailed in these areas and reﬂect the vast
expertise of the task force members. Guidance is provided for
the types of qualitative and quantitative data important for the
evaluation of measurement equivalence before mixing modes in
clinical trials. Multiple viable designs to gather the necessary data
are described for both qualitative and quantitative studies. For
evaluations based on qualitative data, guidelines are offered
about what results deserve increased concern before mixing
modes and recommendations for next steps to resolve these
concerns. For evaluations based on quantitative data, the report
is light, mentioning only one (the intraclass correlation coefﬁcient
[ICC]) of many analyses that could be conducted to assess mea-
surement equivalence. The omission of greater detail for the
quantitative evaluations is disappointing, especially given the
amount of information provided about statistical evaluations
within the previous ePRO task force report by Coons et al. [2],
which focused on the evidence needed to support measurement
equivalence when migrating from paper to an electronic platform.
Review of the Coons et al. [2] report provides additional and
essential details. A randomized crossover design with patients
completing both modes within an appropriate time period is the
best design to provide data for the ICC evaluation. In addition, an
ICC should reach at least 0.70 to make group comparisons and
0.85 to 0.95 to support patient-level decisions [3,4]. Furthermore,
the previous task force pointed out the importance of considering
the measure’s test-retest reliability in its original mode whenial Support: The authors have no other ﬁnancial revaluating the ICC in order not to hold the alternate modes’
evaluation to a higher standard than the original mode’s test-
retest stability. Finally, if the planned quantitative study design
does not support the computation of an ICC (e.g., in the context of
a randomized parallel-group design), then the comparison of the
internal consistency [5] (e.g., Cronbach’s alpha) for each mode
should be considered, along with methods such as item response
theory or differential item functioning.
Given the high-stakes nature of the present task force’s
objective to “address the use and mixing of data collection modes
within and between trials where the PRO endpoints are intended
to be used to support medical product labeling,” increased focus
on the effect of combining scores is necessary. Throughout the
report, recommendations are provided with measurement
equivalence as the goal. As deﬁned by the task force, however,
measurement equivalence is simply “measuring the same
thing”—a lower hurdle that may more adequately be considered
“measurement comparability.” To support “measurement
equivalence” for potential PRO labeling, the recommendations
should include evaluations that patients identiﬁed as “respon-
ders” on one mode are identiﬁed as “responders” on another
mode. One potential approach is to compare cumulative distribu-
tion functions by mode using conﬁdence intervals. A more robust
approach involves evaluating the measurement precision across
the entire score distributions using techniques such as Rasch
measurement theory or item response theory.
What if the results from these evaluations do not support
score equivalence? The recommendations in the report include
an example of the addition of mode in the planned statistical
model. But what if the planned evaluation is a responder
analysis? In this case, it may be necessary to consider equating
scores across modes and then identifying responders on the basis
of equated scores [6]. Although this approach would increase the
complexity of the scoring, the beneﬁts may be worth the effort,
especially in the growing area of rare diseases for which pooling
data is often a necessity.
Overall, the task force report provides practical guidance to
avoid most pitfalls when designing studies involving multiple
modes of data collection. In addition to this sound advice,
however, additional work is needed to provide guidance when
there is evidence that the PRO scores are comparable but not
exactly equal. There are analytical techniques that offer potential
solutions beyond those outlined in the current task force report
(e.g., differential item functioning and equating). As a next step,
task force members and PRO researchers in general should
pursue a reasonable and scientiﬁcally grounded process for bothelationships to disclose.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 4 9 1 – 4 9 2492the development of a thoughtful mixed mode approach and
evaluations of the resulting PRO scores (and conclusions), so that
together we can put forth the best evidence to support high-
stakes PRO end points.
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